Xu Changyi, Liu Ming, Xie Xinran, Li Zhixin, Zhu Yuefei, Ye Yang, Du Mengya, Hu Suhua, Liu Tianrun, Guo Yubiao, Wen Weiping, Liu Huanliang, Tu Zhaoxu
Department of Otolaryngology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
Adv Sci (Weinh). 2025 Apr;12(13):e2412626. doi: 10.1002/advs.202412626. Epub 2025 Feb 14.
Effective management of serious respiratory diseases, such as asthma and recalcitrant rhinitis, remains a global challenge. Here, it is shown that induced sputum supernatants (ISS) from patients with asthma contain higher levels of cell-free DNA (cfDNA) compared to that of healthy volunteers. Although cfDNA scavenging strategies have been developed for inflammation modulation in previous studies, this fall short in clinical settings due to the excessive neutrophil extracellular trap (NET) formation, reactive oxygen and nitrogen species (RONS) and bacterial infections in injured airway tissues. Based on this, a multifunctional boron-based 2D nanoplatform B-P is designed by coating boron nanosheets (B-NS) with polyamidoamine generation 1 (PG1) dendrimer, which can simultaneously target cfDNA, NETs, RONS, and bacteria. The effects of B-P in promoting mucosal repair, reducing airway inflammation, and mucus production have been demonstrated in model mice, and the therapeutic effect is superior to dexamethasone. Furthermore, flow cytometry with clustering analysis and transcriptome analysis with RNA-sequencing are adopted to comprehensively evaluate the in vivo anti-inflammation therapeutic effects. These findings emphasize the significance of a multi-targeting strategy to modulate dysregulated inflammation and highlight multifunctional boron-based 2D nanoplatforms for the amelioration of respiratory inflammatory diseases.
有效管理严重的呼吸道疾病,如哮喘和顽固性鼻炎,仍然是一项全球性挑战。在此,研究表明,与健康志愿者相比,哮喘患者的诱导痰上清液(ISS)中游离细胞DNA(cfDNA)水平更高。尽管在先前的研究中已经开发了cfDNA清除策略用于炎症调节,但由于受损气道组织中过度的中性粒细胞胞外陷阱(NET)形成、活性氧和氮物质(RONS)以及细菌感染,在临床环境中效果不佳。基于此,通过用第1代聚酰胺胺(PG1)树枝状大分子包覆硼纳米片(B-NS)设计了一种多功能硼基二维纳米平台B-P,其可以同时靶向cfDNA、NETs、RONS和细菌。B-P在促进模型小鼠黏膜修复、减轻气道炎症和黏液产生方面的作用已得到证实,且治疗效果优于地塞米松。此外,采用聚类分析的流式细胞术和RNA测序的转录组分析来全面评估体内抗炎治疗效果。这些发现强调了多靶点策略在调节失调炎症中的重要性,并突出了多功能硼基二维纳米平台在改善呼吸道炎症性疾病方面的作用。